Education
About Us
Working with TipRanks
Follow Us
Shin Nippon Biomedical Laboratories, Ltd. (JP:2395)
:2395
2395 Stock Chart & Stats
¥1622.00
¥20.00(1.21%)
At close: 4:00 PM EST
¥1622.00
¥20.00(1.21%)
Day’s Range― - ―
52-Week Range¥1,142.00 - ¥2,005.00
Previous CloseN/A
Volume203.40K
Average Volume (3M)231.41K
Market Cap
¥62.61B
Enterprise Value¥88.73B
Total Cash (Recent Filing)¥11.57B
Total Debt (Recent Filing)¥36.58B
Price to Earnings (P/E)14.4
Beta0.96
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield2.79%
Share Statistics
EPS (TTM)N/A
Shares Outstanding41,632,400
10 Day Avg. Volume314,150
30 Day Avg. Volume231,410
Financial Highlights & Ratios
PEG Ratio-1.10
Price to Book (P/B)1.49
Price to Sales (P/S)1.84
P/FCF Ratio-15.60
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
¥3,400.00Price Target Upside109.62% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Revenue Growth & ProfitabilityConsistent revenue growth and profit generation indicate expanding client demand for outsourced R&D and stable fee-based contracts. Over the medium term this supports predictable revenue visibility, better capacity utilization and reinvestment to sustain technical capabilities and client relationships.
High Gross MarginsA gross margin consistently above 50% signals a structural cost advantage in lab operations and a higher-value service mix. That margin cushion supports reinvestment in capabilities, absorbs pricing pressure, and underpins long-term operating leverage as scale grows across preclinical and clinical services.
Strong Cash ConversionRobust operating cash flow relative to net income shows effective cash conversion from core operations. This strengthens working-capital resilience, funds ordinary growth capex without immediate external funding, and supports durable service delivery capacity and operational continuity.
Bears Say
Declining Net MarginsA trend of falling net profit margins reduces retained earnings and signals pressure on operating efficiency or rising SG&A/other costs. Persisting margin compression can limit reinvestment, lower returns on projects and force cost or pricing changes that could impair long-term competitiveness.
Rising LeverageIncreasing debt-to-equity and higher leverage constrain financial flexibility and elevate fixed obligations. Over months this raises interest and refinancing risk, may restrict ability to fund strategic investments in specialized facilities, and makes cash-flow volatility more consequential to credit standing.
Negative Free Cash FlowSustained negative free cash flow after capex indicates cash shortfalls and potential reliance on external financing. If unresolved, this can strain liquidity, force higher leverage, or curtail necessary facility and equipment investments that underpin long-term service quality and regulatory compliance.
Shin Nippon Biomedical Laboratories, Ltd. News
2395 FAQ
What was Shin Nippon Biomedical Laboratories, Ltd.’s price range in the past 12 months?
Shin Nippon Biomedical Laboratories, Ltd. lowest stock price was ¥1142.00 and its highest was ¥2005.00 in the past 12 months.
What is Shin Nippon Biomedical Laboratories, Ltd.’s market cap?
Shin Nippon Biomedical Laboratories, Ltd.’s market cap is ¥62.61B.
When is Shin Nippon Biomedical Laboratories, Ltd.’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Shin Nippon Biomedical Laboratories, Ltd.’s earnings last quarter?
Currently, no data Available
Is Shin Nippon Biomedical Laboratories, Ltd. overvalued?
According to Wall Street analysts Shin Nippon Biomedical Laboratories, Ltd.’s price is currently Undervalued.
Does Shin Nippon Biomedical Laboratories, Ltd. pay dividends?
Shin Nippon Biomedical Laboratories, Ltd. pays a Semiannually dividend of ¥30 which represents an annual dividend yield of 2.79%. See more information on Shin Nippon Biomedical Laboratories, Ltd. dividends here
What is Shin Nippon Biomedical Laboratories, Ltd.’s EPS estimate?
Shin Nippon Biomedical Laboratories, Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Shin Nippon Biomedical Laboratories, Ltd. have?
Shin Nippon Biomedical Laboratories, Ltd. has 41,632,400 shares outstanding.
What happened to Shin Nippon Biomedical Laboratories, Ltd.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Shin Nippon Biomedical Laboratories, Ltd.?
Currently, no hedge funds are holding shares in JP:2395
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Shin Nippon Biomedical Laboratories, Ltd.
Shin Nippon Biomedical Laboratories, Ltd., a contract research organization, provides drug discovery and development services in Japan and internationally. It offers pre-clinical laboratory services, such as good laboratory practice inspections; general and specific toxicity studies; pathological examinations; PK/PD of biopharmaceuticals, immunotoxicity tests, and antibody production; reproductive and developmental toxicity studies; pharmacology and pharmacological efficacy studies; and imaging services. The company also engages in the establishment and validation of analytical methods, analysis of biological samples, and calculation of pharmacokinetic parameters; and provides absorption, distribution, metabolism, and excretion studies using radioisotope-labeled compounds. In addition, it provides site management organization services for clinical trials; clinical contract research organization services; and translational research services, including research and development of nasal delivery systems, nucleic acid adjuvants, and regenerative medicines. The company was founded in 1957 and is headquartered in Tokyo, Japan.
2395 Stock 12 Month Forecast
Average Price Target
¥3,400.00
▲(109.62% Upside)
Technical Analysis
Options Prices
Currently, No data available
---